NZ703585A - Blood brain barrier shuttle - Google Patents
Blood brain barrier shuttleInfo
- Publication number
- NZ703585A NZ703585A NZ703585A NZ70358513A NZ703585A NZ 703585 A NZ703585 A NZ 703585A NZ 703585 A NZ703585 A NZ 703585A NZ 70358513 A NZ70358513 A NZ 70358513A NZ 703585 A NZ703585 A NZ 703585A
- Authority
- NZ
- New Zealand
- Prior art keywords
- brain barrier
- blood brain
- transferrin receptor
- entity
- monovalent binding
- Prior art date
Links
- 230000008499 blood brain barrier function Effects 0.000 title abstract 3
- 210000001218 blood-brain barrier Anatomy 0.000 title abstract 3
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 4
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 4
- 239000012636 effector Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12182181 | 2012-08-29 | ||
PCT/EP2013/067595 WO2014033074A1 (fr) | 2012-08-29 | 2013-08-26 | Navette de la barrière hémato-encéphalique |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ703585A true NZ703585A (en) | 2018-03-23 |
Family
ID=46963437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ703585A NZ703585A (en) | 2012-08-29 | 2013-08-26 | Blood brain barrier shuttle |
Country Status (27)
Country | Link |
---|---|
US (2) | US20150322149A1 (fr) |
EP (2) | EP3315514A1 (fr) |
JP (3) | JP6219956B2 (fr) |
KR (4) | KR20190121874A (fr) |
CN (2) | CN109053901A (fr) |
AU (3) | AU2013307406B2 (fr) |
BR (1) | BR112015004512B1 (fr) |
CA (1) | CA2879496C (fr) |
DK (1) | DK2890712T3 (fr) |
ES (1) | ES2733324T3 (fr) |
HK (1) | HK1205521A1 (fr) |
HR (1) | HRP20191153T1 (fr) |
HU (1) | HUE045144T2 (fr) |
IL (2) | IL237064A0 (fr) |
LT (1) | LT2890712T (fr) |
MX (2) | MX367126B (fr) |
MY (1) | MY178542A (fr) |
NZ (1) | NZ703585A (fr) |
PL (1) | PL2890712T3 (fr) |
PT (1) | PT2890712T (fr) |
RS (1) | RS58928B1 (fr) |
RU (3) | RU2711552C2 (fr) |
SG (2) | SG10201702702VA (fr) |
SI (1) | SI2890712T1 (fr) |
TR (1) | TR201909156T4 (fr) |
WO (1) | WO2014033074A1 (fr) |
ZA (1) | ZA201500346B (fr) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298834A (zh) | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
SG11201401857WA (en) | 2011-10-28 | 2014-09-26 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
UA115439C2 (uk) | 2012-01-27 | 2017-11-10 | Протена Біосаєнсиз Лімітед | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн |
EA036225B1 (ru) | 2012-03-14 | 2020-10-15 | Ридженерон Фармасьютикалз, Инк. | Мультиспецифические антигенсвязывающие молекулы и их применения |
SG10201702702VA (en) * | 2012-08-29 | 2017-06-29 | Hoffmann La Roche | Blood brain barrier shuttle |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
RU2718990C1 (ru) * | 2013-11-21 | 2020-04-15 | Ф. Хоффманн-Ля Рош Аг | Антитела к альфа-синуклеину и способы применения |
RU2711322C1 (ru) | 2013-12-20 | 2020-01-16 | Ф. Хоффманн-Ля Рош Аг | Улучшенные способы получения рекомбинантного полипептида |
CA2932958A1 (fr) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Anticorps anti-tau(ps422) humanises et leurs methodes d'utilisation |
EP3089996B1 (fr) | 2014-01-03 | 2021-07-28 | F. Hoffmann-La Roche AG | Anticorps bispécifiques anti-récepteur des navettes de la barrière hémato-encéphalique/anti-haptène, complexes de ceux-ci et leur utilisation comme navettes de la barrière hémato-encéphalique |
KR20160105799A (ko) | 2014-01-06 | 2016-09-07 | 에프. 호프만-라 로슈 아게 | 1가 혈액 뇌 장벽 셔틀 모듈 |
EP3129051A1 (fr) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Navettes de la barrière hémato-encéphalique contenant des anticorps reconnaissant l'alpha-synucléine |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
WO2016094881A2 (fr) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Protéines de liaison à lrp-8 |
DK3292149T3 (da) | 2015-05-04 | 2022-02-28 | Cytomx Therapeutics Inc | Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
AU2016280190B9 (en) * | 2015-06-19 | 2022-05-19 | Eisai R&D Management Co., Ltd. | Cys80 conjugated immunoglobulins |
IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
AR105089A1 (es) | 2015-06-24 | 2017-09-06 | Hoffmann La Roche | ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN |
EP3313890A1 (fr) * | 2015-06-24 | 2018-05-02 | H. Hoffnabb-La Roche Ag | Anticorps trispécifiques spécifiques de her2 et d'un récepteur de la barrière hémato-encéphalique et procédés d'utilisation |
CA2997801A1 (fr) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anticorps de recepteur de la transferrine humaine/anti-humaine cd20 bispecifique et leurs procedes d'utilisation |
AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
PL3782639T3 (pl) * | 2015-12-08 | 2022-11-28 | Regeneron Pharmaceuticals, Inc. | Kompozycje i sposoby internalizacji enzymów |
SG11201810801QA (en) * | 2016-07-14 | 2019-01-30 | Bioarctic Ab | Brain delivery protein |
US10702589B2 (en) | 2016-10-04 | 2020-07-07 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Compositions and methods of treating neurological disorder and stress-induced conditions |
KR20190114963A (ko) * | 2016-12-02 | 2019-10-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물 |
RU2711912C2 (ru) * | 2016-12-15 | 2020-01-23 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН) | Аптамер, проходящий через гематоэнцефалический барьер головного мозга мыши |
TW201825123A (zh) * | 2016-12-19 | 2018-07-16 | 南韓商韓美藥品股份有限公司 | 用於腦部靶向的長效蛋白質共軛物 |
KR20190097067A (ko) | 2016-12-26 | 2019-08-20 | 쿄와 기린 가부시키가이샤 | 미엘린 올리고덴드로사이트 당단백질에 결합하는 항체 |
AU2018212860A1 (en) | 2017-01-30 | 2019-08-15 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
MX2019009818A (es) * | 2017-02-17 | 2019-10-14 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados. |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
MX2019012381A (es) * | 2017-05-18 | 2020-01-23 | Hoffmann La Roche | Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico. |
CN111094336A (zh) * | 2017-08-10 | 2020-05-01 | 戴纳立制药公司 | 使用转铁蛋白受体结合蛋白的基于亲和力的方法 |
WO2019036725A2 (fr) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Inhibiteurs peptidiques d'agrégation de tau |
CN107410495B (zh) * | 2017-08-24 | 2018-06-01 | 北京亦贝安生物医药科技有限公司 | 一种酸性乳糖酶和锌的复方制剂及其制备方法 |
CN107412747B (zh) * | 2017-08-24 | 2018-05-22 | 北京亦贝安生物医药科技有限公司 | 一种含有乳铁蛋白和唾液酸的复方制剂 |
WO2019055841A1 (fr) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | Anticorps anti-trem2 et leurs procédés d'utilisation |
CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
EP3694875A1 (fr) | 2017-10-09 | 2020-08-19 | Wisconsin Alumni Research Foundation | Anticorps ciblant des cellules de type souche de glioblastome et leurs procédés d'utilisation |
EP3704149A1 (fr) | 2017-11-02 | 2020-09-09 | Ossianix, Inc. | Peptides de liaison sélectifs pour le tfr améliorés capables de traverser la barrière hémato-encéphalique |
CN116731173A (zh) * | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
KR102012448B1 (ko) * | 2018-02-01 | 2019-08-20 | (주)프론트바이오 | 트리메토벤자미드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 신경병증 통증의 예방 또는 치료용 약학적 조성물 |
KR20190114907A (ko) * | 2018-03-30 | 2019-10-10 | 한미약품 주식회사 | 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물 |
JP2021528437A (ja) | 2018-06-21 | 2021-10-21 | ノヴォ ノルディスク アー/エス | 肥満を治療するための新規化合物 |
CA3105000A1 (fr) | 2018-06-26 | 2020-01-02 | Kyowa Kirin Co., Ltd. | Anticorps se liant a la molecule d'adhesion cellulaire 3 |
EP3816291A4 (fr) | 2018-06-26 | 2022-03-16 | Kyowa Kirin Co., Ltd. | Anticorps se liant au protéoglycane-5 à chondroïtine sulfate |
SG11202101436SA (en) * | 2018-08-22 | 2021-03-30 | Denali Therapeutics Inc | Anti-her2 polypeptides and methods of use thereof |
EP3845648A4 (fr) * | 2018-08-30 | 2022-05-18 | Nexmos Co., Ltd. | Aptamère apte à traverser la barrière hématoencéphalique et son application |
KR20200047937A (ko) | 2018-10-26 | 2020-05-08 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
CN110101847A (zh) * | 2019-05-23 | 2019-08-09 | 北京豪思生物科技有限公司 | 转铁蛋白的应用及包含转铁蛋白的组合物 |
KR20220024637A (ko) | 2019-06-19 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법 |
JP2022537333A (ja) | 2019-06-19 | 2022-08-25 | エフ.ホフマン-ラ ロシュ アーゲー | 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法 |
US20220257542A1 (en) * | 2019-07-30 | 2022-08-18 | Frontbio Inc. | Pharmaceutical composition comprising trimethobenzamide or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating neuropathic pain |
US20220325265A1 (en) | 2019-09-09 | 2022-10-13 | Hoffmann-La Roche Inc. | Glucocerebrosidase mutants |
KR102247568B1 (ko) | 2019-10-11 | 2021-05-04 | 재단법인 대구경북첨단의료산업진흥재단 | 집속초음파 조사 시스템 및 집속초음파를 이용한 혈액뇌장벽 개방 조절 방법 |
BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
IL295797A (en) | 2020-02-22 | 2022-10-01 | Japan Chem Res | Human transfer receptor binding peptide |
EP4110794A1 (fr) | 2020-02-25 | 2023-01-04 | Vib Vzw | Modulateurs allostériques de la kinase à répétitions riches en leucines 2 |
AU2021362209A1 (en) | 2020-10-14 | 2023-05-18 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
KR20240019125A (ko) | 2021-06-11 | 2024-02-14 | 바이오악틱 에이비 | 이중특이적 결합 분자 |
EP4373853A2 (fr) * | 2021-07-21 | 2024-05-29 | Icahn School of Medicine at Mount Sinai | Anticorps anti-fsh contre des maladies neurodégénératives |
TW202321274A (zh) | 2021-08-19 | 2023-06-01 | 日商Jcr製藥股份有限公司 | 人類運鐵蛋白受體結合肽 |
IL311025A (en) | 2021-08-24 | 2024-04-01 | Peptidream Inc | Human receptor binding antibody-peptides |
IL311175A (en) | 2021-09-01 | 2024-04-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and their uses |
WO2023055155A1 (fr) * | 2021-10-01 | 2023-04-06 | 서울대학교산학협력단 | Peptide destiné à traverser la barrière hémato-encéphalique et son utilisation |
WO2023128702A1 (fr) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et ses utilisations |
KR102575322B1 (ko) * | 2021-12-31 | 2023-09-08 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
WO2023198661A1 (fr) | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Protéines de fusion ciblées sur le système nerveux central |
WO2024008755A1 (fr) | 2022-07-04 | 2024-01-11 | Vib Vzw | Anticorps de traversée de barrière de fluide céphalorachidien |
WO2024080843A1 (fr) * | 2022-10-14 | 2024-04-18 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et son utilisation |
WO2024091079A1 (fr) * | 2022-10-28 | 2024-05-02 | 주식회사 아임뉴런 | Protéine de fusion perméable à la barrière hémato-encéphalique et ses utilisations |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス,インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
EP1068241B1 (fr) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Variants d'anticorps et fragments de ceux-ci |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
CA2376693C (fr) * | 1999-06-16 | 2013-09-10 | Boston Biomedical Research Institute | Temoin immunologique de niveaux de .beta.-amyloide in vivo |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US6849032B2 (en) * | 2002-11-20 | 2005-02-01 | Fitness Botics, Inc. | Exercise apparatus simulating skating motions |
US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
RS54450B1 (en) | 2003-11-05 | 2016-06-30 | Roche Glycart Ag | ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION |
EP2377886A1 (fr) * | 2005-12-12 | 2011-10-19 | F. Hoffmann-La Roche AG | Glycosylation d'anticorps pour la région variable |
DE102006013531A1 (de) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
AU2009296297A1 (en) * | 2008-09-26 | 2010-04-01 | Roche Glycart Ag | Bispecific anti-EGFR/anti-IGF-1R antibodies |
CN102369215B (zh) * | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
AR084020A1 (es) * | 2010-11-30 | 2013-04-17 | Genentech Inc | Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
SG10201702702VA (en) * | 2012-08-29 | 2017-06-29 | Hoffmann La Roche | Blood brain barrier shuttle |
-
2013
- 2013-08-26 SG SG10201702702VA patent/SG10201702702VA/en unknown
- 2013-08-26 ES ES13756076T patent/ES2733324T3/es active Active
- 2013-08-26 SI SI201331492T patent/SI2890712T1/sl unknown
- 2013-08-26 TR TR2019/09156T patent/TR201909156T4/tr unknown
- 2013-08-26 EP EP17199410.6A patent/EP3315514A1/fr active Pending
- 2013-08-26 RS RS20190813A patent/RS58928B1/sr unknown
- 2013-08-26 CN CN201810972126.3A patent/CN109053901A/zh active Pending
- 2013-08-26 PL PL13756076T patent/PL2890712T3/pl unknown
- 2013-08-26 WO PCT/EP2013/067595 patent/WO2014033074A1/fr active Application Filing
- 2013-08-26 RU RU2018127006A patent/RU2711552C2/ru active
- 2013-08-26 HU HUE13756076A patent/HUE045144T2/hu unknown
- 2013-08-26 MX MX2015002215A patent/MX367126B/es active IP Right Grant
- 2013-08-26 KR KR1020197030778A patent/KR20190121874A/ko not_active Application Discontinuation
- 2013-08-26 LT LTEP13756076.9T patent/LT2890712T/lt unknown
- 2013-08-26 BR BR112015004512-0A patent/BR112015004512B1/pt active IP Right Grant
- 2013-08-26 PT PT13756076T patent/PT2890712T/pt unknown
- 2013-08-26 KR KR1020187021343A patent/KR102036262B1/ko active IP Right Grant
- 2013-08-26 JP JP2015528977A patent/JP6219956B2/ja active Active
- 2013-08-26 CN CN201380042265.1A patent/CN104520329A/zh active Pending
- 2013-08-26 KR KR1020177009426A patent/KR101885044B1/ko not_active Application Discontinuation
- 2013-08-26 NZ NZ703585A patent/NZ703585A/en unknown
- 2013-08-26 MY MYPI2015000168A patent/MY178542A/en unknown
- 2013-08-26 SG SG11201500583PA patent/SG11201500583PA/en unknown
- 2013-08-26 CA CA2879496A patent/CA2879496C/fr active Active
- 2013-08-26 KR KR20157004942A patent/KR20150039798A/ko active Application Filing
- 2013-08-26 RU RU2015111093A patent/RU2663120C2/ru active
- 2013-08-26 AU AU2013307406A patent/AU2013307406B2/en active Active
- 2013-08-26 DK DK13756076.9T patent/DK2890712T3/da active
- 2013-08-26 EP EP13756076.9A patent/EP2890712B1/fr active Active
-
2015
- 2015-01-16 ZA ZA2015/00346A patent/ZA201500346B/en unknown
- 2015-02-02 US US14/611,964 patent/US20150322149A1/en not_active Abandoned
- 2015-02-02 IL IL237064A patent/IL237064A0/en active IP Right Grant
- 2015-02-19 MX MX2019006259A patent/MX2019006259A/es unknown
- 2015-06-25 HK HK15106064.1A patent/HK1205521A1/xx unknown
-
2017
- 2017-09-28 JP JP2017187722A patent/JP2018029602A/ja active Pending
-
2018
- 2018-05-15 AU AU2018203400A patent/AU2018203400B2/en active Active
- 2018-12-19 US US16/225,370 patent/US20190276530A1/en not_active Abandoned
-
2019
- 2019-06-26 HR HRP20191153TT patent/HRP20191153T1/hr unknown
- 2019-09-12 JP JP2019166422A patent/JP6889218B2/ja active Active
- 2019-12-20 RU RU2019142838A patent/RU2754794C2/ru active
-
2020
- 2020-07-31 AU AU2020210286A patent/AU2020210286A1/en not_active Abandoned
- 2020-11-22 IL IL278872A patent/IL278872A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ703585A (en) | Blood brain barrier shuttle | |
MX2020013057A (es) | Modulos de lanzadera de barrera cerebral sanguinea monovalente. | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
MX2020010399A (es) | 3-epimerasa. | |
RU2021134101A (ru) | Модифицированная j-цепь | |
MX2015006548A (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
NZ628446A (en) | Fibronectin based scaffold domain proteins that bind to myostatin | |
NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
MX2013001845A (es) | Polipetidos que enlazan miostatina, composiciones y metodos. | |
BR112015022978A8 (pt) | tecnologias de multimerização | |
IN2015DN02577A (fr) | ||
NZ607969A (en) | Cd33 binding agents | |
WO2012031250A8 (fr) | Compositions de marquage de nerfs et procédés d'utilisation | |
MX353706B (es) | Anticuerpos contra csf-1r humano y usos de los mismos. | |
NZ612161A (en) | Radiolabled her2 binding peptides | |
MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
PH12014501083A1 (en) | Anticancer fusion protein | |
NZ628625A (en) | Polypeptides binding to human complement c5 | |
MX2016008189A (es) | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. | |
NZ630847A (en) | Anti-sema4d antibodies and epitopes | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
WO2014057436A3 (fr) | Conjugué anticancéreux | |
NZ607720A (en) | Peptide or peptide complex binding to 2 integrin and methods and uses involving the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2019 BY THOMSON REUTERS Effective date: 20180721 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2020 BY THOMSON REUTERS Effective date: 20190725 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2021 BY THOMSON REUTERS Effective date: 20200721 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2022 BY THOMSON REUTERS Effective date: 20210702 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2023 BY THOMSON REUTERS Effective date: 20220704 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2024 BY ANAQUA SERVICES Effective date: 20230720 |